HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Prelude Therapeutics (NASDAQ:PRLD) and maintained a price target of $17.
August 17, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prelude Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $17.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $17 also indicates the firm's confidence in the stock's potential. This could lead to increased investor interest and potentially a short-term increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100